Investors sold shares of Insulet Corporation (NASDAQ:PODD) on strength during trading on Monday. $4.17 million flowed into the stock on the tick-up and $44.85 million flowed out of the stock on the tick-down, for a money net flow of $40.68 million out of the stock. Of all stocks tracked, Insulet Corporation had the 0th highest net out-flow for the day. Insulet Corporation traded up $0.59 for the day and closed at $55.67

A number of analysts have recently issued reports on the company. Barclays PLC assumed coverage on Insulet Corporation in a research report on Friday, September 15th. They set an “overweight” rating and a $65.00 target price on the stock. Zacks Investment Research upgraded Insulet Corporation from a “hold” rating to a “buy” rating and set a $57.00 price target on the stock in a research note on Tuesday, July 18th. BTIG Research downgraded Insulet Corporation from a “buy” rating to a “neutral” rating in a report on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating on shares of Insulet Corporation in a report on Friday, June 16th. Finally, BidaskClub upgraded Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 25th. Eight analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $51.50.

The company has a 50-day moving average price of $57.25 and a 200-day moving average price of $48.65. The firm’s market capitalization is $3.25 billion.

Insulet Corporation (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.13). Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.74%. The business had revenue of $110.00 million during the quarter, compared to analyst estimates of $106.23 million. During the same quarter in the prior year, the business earned ($0.08) earnings per share. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, analysts forecast that Insulet Corporation will post ($0.51) EPS for the current year.

In other news, EVP Charles Alpuche purchased 2,500 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was purchased at an average price of $58.08 per share, with a total value of $145,200.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.60% of the company’s stock.

Large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Insulet Corporation by 11.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after purchasing an additional 235 shares during the period. Strs Ohio raised its stake in shares of Insulet Corporation by 73.9% in the first quarter. Strs Ohio now owns 4,000 shares of the medical instruments supplier’s stock valued at $172,000 after purchasing an additional 1,700 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Insulet Corporation in the second quarter valued at $180,000. Teacher Retirement System of Texas acquired a new position in shares of Insulet Corporation in the first quarter valued at $201,000. Finally, Diversified Trust Co acquired a new position in shares of Insulet Corporation in the second quarter valued at $205,000.

WARNING: “Investors Sell Shares of Insulet Corporation (PODD) on Strength (PODD)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/10/04/investors-sell-shares-of-insulet-corporation-podd-on-strength-podd.html.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.